Canadian generic pharmaceuticals company Mint Pharmaceuticals Inc announced on Thursday that it has agreed a new distribution partnership with Bayer Canada, a subsidiary of German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY).
The agreement covers the distribution of ADALAT XL (nifedipine extended-release) 30 mg tablets in Canada. First authorised in the Canadian market in 1995, the drug is indicated for the management of chronic stable angina and the management of mild to moderate essential hypertension.
Through the collaboration, Mint Pharmaceuticals and Bayer Canada aim to enhance the accessibility and availability of ADALAT XL to healthcare providers and patients across Canada.
Jaiveer Singh, CEO of Mint Pharmaceuticals, said: "With a best-in-class supply chain built over the past 15 years, Mint is proud to bring that strength to the distribution of ADALAT XL, ensuring Canadians have seamless access to this trusted therapy."
Aurisco Pharmaceutical reports successful US FDA inspection
Dr. Reddy's launches first-to-market sugammadex injection in the US
Par Health launches generic version of Janumet XR tablets in US
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Lupin announces US launch of Azilsartan Medoxomil Tablets
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic